PMID-32342318 – Functional Connectomic Approach to Semax and Selank Effects
Panikratova YR et al., "Functional connectomic approach to studying Semax and Selank effects on brain functional connectivity," Dokl Biol Sci, 2020;491(1):38-40. DOI: 10.1134/S001249662001007X
Quick Reference
| Property | Value |
|---|---|
| PMID | 32342318 |
| DOI | 10.1134/S001249662001007X |
| Year | 2020 |
| Journal | Doklady Biological Sciences |
| Study Type | Observational (human interventional fMRI) |
| Evidence Level | III |
| Sample | 52 healthy adult volunteers |
| Peptide(s) Studied | Semax, Selank |
Key Findings
- Resting-state fMRI demonstrated that both intranasal Semax and Selank produced significant changes in functional connectivity between the right amygdala and temporal cortex regions at 5 and 20 minutes post-administration.
- This represents the first human neuroimaging evidence confirming that both peptides exert measurable central nervous system effects after intranasal delivery.
- The amygdala-temporal connectivity changes suggest modulation of emotional processing and salience networks, consistent with the anxiolytic profile of Selank and the cognitive-enhancing profile of Semax.
Study Design
Randomized, controlled human study in 52 healthy adults. Participants received intranasal Semax, Selank, or placebo. Resting-state fMRI scans were acquired at baseline and at 5 and 20 minutes post-administration. Functional connectivity was analyzed using seed-based correlation with the amygdala as the primary region of interest.
Limitations
- Short observation window (20 minutes); longer-term connectivity changes were not assessed.
- Relatively small sample per group after randomization into three arms.
Clinical Relevance
Provides critical human-level evidence that intranasal Semax and Selank reach the brain and alter functional connectivity in emotion- and cognition-relevant circuits, bridging the gap between animal mechanistic data and clinical application.
Related
#research #observational #evidence-level-III